Many active young women use oral contraceptives (OC) yet its effect on their body composition and exercise performance has not been thoroughly studied. A team of researchers has now examined the effects of OC on female muscle mass, and found that oral contraceptive use impairs muscle gains in young women, and is associated with lower hormone levels.
The findings are contained in a new study entitled Oral Contraceptive Use Impairs Muscle Gains in Young Women. It was conducted by Chang-Woock Lee and Steven E. Riechman, Department of Health and Kinesiology, Texas A&M University, College Station, TX; and Mark A. Newman, Human Energy Research Laboratory, University of Pittsburgh, Pittsburgh, PA. The researchers will present their findings at the 122nd Annual Meeting of the American Physiological Society, which is part of the Experimental Biology 2009 scientific conference. The meeting will be held April 18-22, 2009 in New Orleans.
The Study
Seventy-three generally healthy women between the ages of 18-31 were assigned to two groups and completed a 10-week whole-body resistance exercise training (RET). Group 1 consisted of 34 women who used oral contraceptives (OC). Group 2 consisted of 39 women who did not take birth control pills (non-OC). The women were encouraged to consume at least 0.5 grams of protein per pound of body weight per day (a third more than is called for by the U.S. government nutritional guidelines) to make sure they consumed enough calories and protein to promote muscle growth.
The participants exercised three times per week for ten weeks under the supervision of exercise physiologists. They performed a variety of exercises to include chest press, lat pull down, leg extension, triceps extension, arm curl and abdominal crunch. Exercise was done using standard exercise machines and each volunteer performed three sets of 6-10 repetitions per exercise at 75 percent of their maximum strength. Body composition was determined using hydrostatic weighing.
Blood samples were taken before and after the training and assessed to measure anabolic (muscle building) and catabolic (muscle breaking) hormone levels in blood. Resting and fasting blood concentrations were measured for three anabolic hormones: DHEA, DHEAS and IGF1.
Findings
The researchers found that:
-- there were significant differences in lean mass gains (OC: 2.1?±2.1% vs. non-OC: 3.5?±3.2% / OC: 1.0?±1.0kg vs. no-OC: 1.6?±1.4kg, p
четверг, 26 апреля 2012 г.
четверг, 19 апреля 2012 г.
Bionovo's MF101 Shows Positive Safety, Tolerability And Efficacy In Phase 2 Trial
Bionovo, Inc.'s
(Nasdaq: BNVI) lead drug candidate, MF101, showed positive Phase 2 results
for the treatment of hot flashes associated with menopause. Two hundred and
seventeen women were enrolled in the company's double-blind, placebo-
controlled, randomized Phase 2 trial. Postmenopausal women with 50 or more
moderate to severe hot flashes per week were randomized to one of three
treatment groups receiving MF101 (5 grams/day), MF101 (10 grams/day), or
placebo for twelve weeks. The trial was led by Dr. Deborah Grady at the
University of California, San Francisco and was conducted at six medical
centers in the United States: University of California, San Francisco,
University of Minnesota, Minneapolis, University of Pittsburgh, University
of Tennessee, Memphis, University of Alabama, Birmingham and the San Diego
Medical Center for Clinical Research.
Bionovo's primary objectives in the Phase 2 clinical trial were to
assess the safety, tolerability and the potential efficacy of two doses of
MF101 to reduce the frequency and severity of hot flashes. Both doses of
MF101 were more effective than placebo at reducing the frequency and
severity of hot flashes from the start of the trial until the end of the
treatment period 12 weeks later. In a paired t-test, comparing the number
of hot flashes per day after 12 weeks of treatment, MF101 5 gm was better
than placebo at 12 weeks but did not reach statistical significance
(p=0.06). The higher dose was statistically superior to placebo with a p
value of 0.05 and both doses combined were superior to placebo with a p
value of 0.04. MF101 showed a trend for improvement in severity of hot
flashes compared to placebo with the higher dose showing greater
improvement (p=0.1) than the lower dose (p=0.12) and with both doses
combined superior to placebo (p=0.08). There was a dose response trend
suggesting that the higher dose of MF101 was more effective at reducing
both frequency and severity of hot flashes than the lower dose.
In secondary analyses, the percent of women reporting greater than 50%
reduction in all hot flashes was statistically significantly higher in the
MF101 high dose group compared to placebo (p=0.03) and in both doses of
MF101 combined compared to placebo (p=0.05).
MF101 is a novel estrogen receptor beta agonist that is expected not to
stimulate the endometrium or breast tissue. Safety analyses showed no cases
of endometrial hyperplasia or uterine cancer during the trial and there
were no differences in incidence of vaginal bleeding between the placebo
group and the two cohorts treated with MF101. The only side effect that
increased with MF101 treatment was loose stool/diarrhea (12% in each of the
drug arms vs. 3% in placebo arm). Constipation was improved with MF101
therapy. These observations are consistent with the presence of soluble
fiber in the drug extract, which future optimization of the manufacturing
process will significantly reduce. Adherence to the study medication was
high with 91% of the participants compliant with treatment after 12 weeks
of therapy.
"I am very encouraged and pleased by the findings of this clinical
trial," said Deborah Grady, M.D., Associate Dean for Clinical and
Translational Science, Professor of Medicine and Director of the University
of California, San Francisco (UCSF) Women's Health Clinical Research
Center. "The combination of a trend to better efficacy with a higher dose
of MF101 and a very strong safety profile of a drug that was very well
tolerated by menopausal women is exciting news. These early positive
clinical results are not only encouraging for discovering a safer therapy
for hot flashes but also support the role of estrogen receptor beta as a
novel target for treating menopausal symptoms."
"Recent clinical trials, such as the HERS and the WHI, elucidated
important safety concerns of postmenopausal hormone therapy and resulted in
significantly fewer women using these products," said Isaac Cohen, CEO of
Bionovo. "For this reason, it is important for us to find safer
alternatives for treating menopausal symptoms. The favorable dose response
trend signals that MF101 may become a clear alternative to traditional
postmenopausal hormone therapy for relief of vasomotor symptoms. We are
excited by the prospect of moving forward with the development of a product
that could potentially have such broad reach and positively affect the
quality of life for millions of women and their loved ones. This first
Phase 2 trial conducted by Bionovo serves as a proof of our drug
development strategy and we look forward to advancing MF101 into
registration trials."
About MF101
MF101 is an estrogen receptor (ER) beta selective drug developed as an
alternative to postmenopausal hormone products currently on the market,
which are both ER beta and ER alpha agonists that have been shown to
increase the risk for breast and uterine cancers. It has been shown that
the increased risk of breast and uterine cancers is associated with ER
alpha activation and that ER beta blocks the growth promoting effects on
breast cancer cells. Bionovo recognized the opportunity to commercialize a
product that would be equally effective, with an improved safety profile
compared to traditional hormone therapy. The clinical trial results have
been evaluated by an independent Data and Safety Monitoring Board and the
drug candidate has passed through a standard two-phase examination for
safety.
Bionovo, Inc.
Bionovo is a drug development company focusing on the discovery of
novel pharmaceutical agents for cancer and women's health. The company has
two drugs in clinical testing. MF101 has completed Phase 2 for quality of
life conditions associated with menopause, and BZL101 is in Phase 1/2 for
the treatment of advanced breast cancer. The company has an additional
pipeline of drugs in development for breast cancer, pancreatic cancer and
other menopausal symptoms. The company is developing its products in close
collaboration with leading U.S. academic research centers including:
University of California, San Francisco, University of California, Davis,
and the University of Colorado Health Sciences Center. For further
information please visit: bionovo.
Forward-Looking Statements
This release contains certain forward-looking statements relating to
the business of Bionovo, Inc. that can be identified by the use of
forward-looking terminology such as "believes," "expects," or similar
expressions. Such forward-looking statements involve known and unknown
risks and uncertainties, including uncertainties relating to product
development, efficacy and safety, regulatory actions or delays, the ability
to obtain or maintain patent or other proprietary intellectual property
protection, market acceptance, physician acceptance, third party
reimbursement, future capital requirements, competition in general and
other factors that may cause actual results to be materially different from
those described herein as anticipated, believed, estimated or expected.
Certain of these risks and uncertainties are or will be described in
greater detail in our filings with the Securities and Exchange Commission,
which are available at sec. Bionovo, Inc. is under no
obligation (and expressly disclaims any such obligation) to update or alter
its forward-looking statements whether as a result of new information,
future events or otherwise.
Bionovo, Inc.
bionovo
(Nasdaq: BNVI) lead drug candidate, MF101, showed positive Phase 2 results
for the treatment of hot flashes associated with menopause. Two hundred and
seventeen women were enrolled in the company's double-blind, placebo-
controlled, randomized Phase 2 trial. Postmenopausal women with 50 or more
moderate to severe hot flashes per week were randomized to one of three
treatment groups receiving MF101 (5 grams/day), MF101 (10 grams/day), or
placebo for twelve weeks. The trial was led by Dr. Deborah Grady at the
University of California, San Francisco and was conducted at six medical
centers in the United States: University of California, San Francisco,
University of Minnesota, Minneapolis, University of Pittsburgh, University
of Tennessee, Memphis, University of Alabama, Birmingham and the San Diego
Medical Center for Clinical Research.
Bionovo's primary objectives in the Phase 2 clinical trial were to
assess the safety, tolerability and the potential efficacy of two doses of
MF101 to reduce the frequency and severity of hot flashes. Both doses of
MF101 were more effective than placebo at reducing the frequency and
severity of hot flashes from the start of the trial until the end of the
treatment period 12 weeks later. In a paired t-test, comparing the number
of hot flashes per day after 12 weeks of treatment, MF101 5 gm was better
than placebo at 12 weeks but did not reach statistical significance
(p=0.06). The higher dose was statistically superior to placebo with a p
value of 0.05 and both doses combined were superior to placebo with a p
value of 0.04. MF101 showed a trend for improvement in severity of hot
flashes compared to placebo with the higher dose showing greater
improvement (p=0.1) than the lower dose (p=0.12) and with both doses
combined superior to placebo (p=0.08). There was a dose response trend
suggesting that the higher dose of MF101 was more effective at reducing
both frequency and severity of hot flashes than the lower dose.
In secondary analyses, the percent of women reporting greater than 50%
reduction in all hot flashes was statistically significantly higher in the
MF101 high dose group compared to placebo (p=0.03) and in both doses of
MF101 combined compared to placebo (p=0.05).
MF101 is a novel estrogen receptor beta agonist that is expected not to
stimulate the endometrium or breast tissue. Safety analyses showed no cases
of endometrial hyperplasia or uterine cancer during the trial and there
were no differences in incidence of vaginal bleeding between the placebo
group and the two cohorts treated with MF101. The only side effect that
increased with MF101 treatment was loose stool/diarrhea (12% in each of the
drug arms vs. 3% in placebo arm). Constipation was improved with MF101
therapy. These observations are consistent with the presence of soluble
fiber in the drug extract, which future optimization of the manufacturing
process will significantly reduce. Adherence to the study medication was
high with 91% of the participants compliant with treatment after 12 weeks
of therapy.
"I am very encouraged and pleased by the findings of this clinical
trial," said Deborah Grady, M.D., Associate Dean for Clinical and
Translational Science, Professor of Medicine and Director of the University
of California, San Francisco (UCSF) Women's Health Clinical Research
Center. "The combination of a trend to better efficacy with a higher dose
of MF101 and a very strong safety profile of a drug that was very well
tolerated by menopausal women is exciting news. These early positive
clinical results are not only encouraging for discovering a safer therapy
for hot flashes but also support the role of estrogen receptor beta as a
novel target for treating menopausal symptoms."
"Recent clinical trials, such as the HERS and the WHI, elucidated
important safety concerns of postmenopausal hormone therapy and resulted in
significantly fewer women using these products," said Isaac Cohen, CEO of
Bionovo. "For this reason, it is important for us to find safer
alternatives for treating menopausal symptoms. The favorable dose response
trend signals that MF101 may become a clear alternative to traditional
postmenopausal hormone therapy for relief of vasomotor symptoms. We are
excited by the prospect of moving forward with the development of a product
that could potentially have such broad reach and positively affect the
quality of life for millions of women and their loved ones. This first
Phase 2 trial conducted by Bionovo serves as a proof of our drug
development strategy and we look forward to advancing MF101 into
registration trials."
About MF101
MF101 is an estrogen receptor (ER) beta selective drug developed as an
alternative to postmenopausal hormone products currently on the market,
which are both ER beta and ER alpha agonists that have been shown to
increase the risk for breast and uterine cancers. It has been shown that
the increased risk of breast and uterine cancers is associated with ER
alpha activation and that ER beta blocks the growth promoting effects on
breast cancer cells. Bionovo recognized the opportunity to commercialize a
product that would be equally effective, with an improved safety profile
compared to traditional hormone therapy. The clinical trial results have
been evaluated by an independent Data and Safety Monitoring Board and the
drug candidate has passed through a standard two-phase examination for
safety.
Bionovo, Inc.
Bionovo is a drug development company focusing on the discovery of
novel pharmaceutical agents for cancer and women's health. The company has
two drugs in clinical testing. MF101 has completed Phase 2 for quality of
life conditions associated with menopause, and BZL101 is in Phase 1/2 for
the treatment of advanced breast cancer. The company has an additional
pipeline of drugs in development for breast cancer, pancreatic cancer and
other menopausal symptoms. The company is developing its products in close
collaboration with leading U.S. academic research centers including:
University of California, San Francisco, University of California, Davis,
and the University of Colorado Health Sciences Center. For further
information please visit: bionovo.
Forward-Looking Statements
This release contains certain forward-looking statements relating to
the business of Bionovo, Inc. that can be identified by the use of
forward-looking terminology such as "believes," "expects," or similar
expressions. Such forward-looking statements involve known and unknown
risks and uncertainties, including uncertainties relating to product
development, efficacy and safety, regulatory actions or delays, the ability
to obtain or maintain patent or other proprietary intellectual property
protection, market acceptance, physician acceptance, third party
reimbursement, future capital requirements, competition in general and
other factors that may cause actual results to be materially different from
those described herein as anticipated, believed, estimated or expected.
Certain of these risks and uncertainties are or will be described in
greater detail in our filings with the Securities and Exchange Commission,
which are available at sec. Bionovo, Inc. is under no
obligation (and expressly disclaims any such obligation) to update or alter
its forward-looking statements whether as a result of new information,
future events or otherwise.
Bionovo, Inc.
bionovo
четверг, 12 апреля 2012 г.
Hormone Drug Type Makes Survival Difference In Advanced Breast Cancer
Aromatase inhibitors, a type of hormone therapy used to treat advanced breast cancer in postmenopausal women, result in a small but significant increase in overall survival when compared to other hormone treatments, according to a new systematic review of studies.
In addition, aromatase inhibitors -- drugs known as Arimidex, Aromasin and Femara -- are less likely to cause blood clots and vaginal bleeding than other hormone treatments, said review co-author Judith Bliss of the Institute of Cancer Research in London.
The review analyzed 30 studies involving the treatment of advanced breast cancer, encompassing more than 10,000 postmenopausal women.
Bliss and colleagues were surprised at how few of the reviewed studies presented data on overall survival for women taking aromatase inhibitors. "Survival data was only available for about half of the women," Bliss said.
The available data showed an 11 percent reduction in the risk of death compared to women not receiving aromatase inhibitors.
The review appears in the current issue of The Cochrane Library, a publication of The Cochrane Collaboration, an international organization that evaluates medical research. Systematic reviews draw evidence-based conclusions about medical practice after considering both the content and quality of existing medical trials on a topic.
The treatment of advanced breast cancer in women who have gone through menopause usually involves a combination of surgery, radiation, chemotherapy, hormonal and biological therapies. In many breast cancers, estrogen stimulates tumor growth. Aromatase inhibitors work by limiting a woman's production of estrogen.
Several aromatase inhibitors, including anastrozole (Arimidex), exemestane (Aromasin) and letrozole (Femara) have been available for clinical use for the past decade or so.
Other breast cancer treatments that also affect estrogen include tamoxifen and progestins. Tamoxifen is the most widely used hormonal treatment in advanced breast cancer; however, it carries a risk of blood clots and other rare but potentially serious side effects.
Bliss said that the review found very little reliable data in the trials comparing the effectiveness of the different available aromatase inhibitors. "The promotion of one individual drug over another is not evidence-based and should be avoided," the authors said.
In general, women taking aromatase inhibitors had about the same risk of experiencing hot flashes as those receiving tamoxifen. However, they reported more nausea, vomiting and diarrhea when compared to patients receiving the progestin drug megestrol acetate and to a lesser extent, when compared with patients receiving tamoxifen.
Patients taking aromatase inhibitors had a decreased risk of vaginal bleeding and blood clots compared to those using other hormonal therapies.
Safety data were difficult to analyze, Bliss said: "The picture is patchy due to poor quality of adverse event reporting and different study endpoints," in the various trials.
However, "the review findings do confirm modest, but real therapeutic benefits from the use of aromatase inhibitors in a variety of clinical settings," Bliss said.
Edith Perez, M.D., an oncologist with the Multidisciplinary Breast Cancer Program at the Mayo Clinic in Jacksonville, Fla., said, "The results of the review are not a surprise. These are good drugs and they have positively impacted the lives of patients with breast cancer." Perez is not associated with the review.
Perez believes that aromatase inhibitors are the first drug of choice for hormonal treatment of advanced breast cancer in postmenopausal women. "They have a slightly improved efficacy over tamoxifen, and they have a much lower rate of blood clots in the legs and lungs," she said. "Aromatase inhibitors carry almost no risk of uterine cancer, and while that rarely happens with tamoxifen, it does happen."
On the other hand, Perez said that aromatase inhibitors do carry a risk of increased joint aches and, more importantly, may cause bone loss. "The majority of patients do very well but we recommend patients have bone density tests before using these drugs. I would probably not use aromatase inhibitors in a patient with severe osteoporosis."
While per-tablet cost of aromatase inhibitors is higher than tamoxifen, Perez said that they are still cost-effective because they have fewer side effects requiring treatment and they result in increased overall survival.
"It's no question that these drugs are better for patients when compared with other hormone therapies," Perez said.
Katherine Kahn, Contributing Writer Health Behavior News Service
Gibson LJ, Dawson, CL, Lawrence DJ, Bliss JM. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women (Review). Cochrane Database of Systematic Reviews 2007, Issue 1.
The Cochrane Collaboration is an international nonprofit, independent organization that produces and disseminates systematic reviews of health care interventions and promotes the search for evidence in the form of clinical trials and other studies of interventions. Visit cochrane/ for more information.
Contact: Lisa Esposito
Center for the Advancement of Health
View drug information on Arimidex; Aromasin Tablets; Femara.
In addition, aromatase inhibitors -- drugs known as Arimidex, Aromasin and Femara -- are less likely to cause blood clots and vaginal bleeding than other hormone treatments, said review co-author Judith Bliss of the Institute of Cancer Research in London.
The review analyzed 30 studies involving the treatment of advanced breast cancer, encompassing more than 10,000 postmenopausal women.
Bliss and colleagues were surprised at how few of the reviewed studies presented data on overall survival for women taking aromatase inhibitors. "Survival data was only available for about half of the women," Bliss said.
The available data showed an 11 percent reduction in the risk of death compared to women not receiving aromatase inhibitors.
The review appears in the current issue of The Cochrane Library, a publication of The Cochrane Collaboration, an international organization that evaluates medical research. Systematic reviews draw evidence-based conclusions about medical practice after considering both the content and quality of existing medical trials on a topic.
The treatment of advanced breast cancer in women who have gone through menopause usually involves a combination of surgery, radiation, chemotherapy, hormonal and biological therapies. In many breast cancers, estrogen stimulates tumor growth. Aromatase inhibitors work by limiting a woman's production of estrogen.
Several aromatase inhibitors, including anastrozole (Arimidex), exemestane (Aromasin) and letrozole (Femara) have been available for clinical use for the past decade or so.
Other breast cancer treatments that also affect estrogen include tamoxifen and progestins. Tamoxifen is the most widely used hormonal treatment in advanced breast cancer; however, it carries a risk of blood clots and other rare but potentially serious side effects.
Bliss said that the review found very little reliable data in the trials comparing the effectiveness of the different available aromatase inhibitors. "The promotion of one individual drug over another is not evidence-based and should be avoided," the authors said.
In general, women taking aromatase inhibitors had about the same risk of experiencing hot flashes as those receiving tamoxifen. However, they reported more nausea, vomiting and diarrhea when compared to patients receiving the progestin drug megestrol acetate and to a lesser extent, when compared with patients receiving tamoxifen.
Patients taking aromatase inhibitors had a decreased risk of vaginal bleeding and blood clots compared to those using other hormonal therapies.
Safety data were difficult to analyze, Bliss said: "The picture is patchy due to poor quality of adverse event reporting and different study endpoints," in the various trials.
However, "the review findings do confirm modest, but real therapeutic benefits from the use of aromatase inhibitors in a variety of clinical settings," Bliss said.
Edith Perez, M.D., an oncologist with the Multidisciplinary Breast Cancer Program at the Mayo Clinic in Jacksonville, Fla., said, "The results of the review are not a surprise. These are good drugs and they have positively impacted the lives of patients with breast cancer." Perez is not associated with the review.
Perez believes that aromatase inhibitors are the first drug of choice for hormonal treatment of advanced breast cancer in postmenopausal women. "They have a slightly improved efficacy over tamoxifen, and they have a much lower rate of blood clots in the legs and lungs," she said. "Aromatase inhibitors carry almost no risk of uterine cancer, and while that rarely happens with tamoxifen, it does happen."
On the other hand, Perez said that aromatase inhibitors do carry a risk of increased joint aches and, more importantly, may cause bone loss. "The majority of patients do very well but we recommend patients have bone density tests before using these drugs. I would probably not use aromatase inhibitors in a patient with severe osteoporosis."
While per-tablet cost of aromatase inhibitors is higher than tamoxifen, Perez said that they are still cost-effective because they have fewer side effects requiring treatment and they result in increased overall survival.
"It's no question that these drugs are better for patients when compared with other hormone therapies," Perez said.
Katherine Kahn, Contributing Writer Health Behavior News Service
Gibson LJ, Dawson, CL, Lawrence DJ, Bliss JM. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women (Review). Cochrane Database of Systematic Reviews 2007, Issue 1.
The Cochrane Collaboration is an international nonprofit, independent organization that produces and disseminates systematic reviews of health care interventions and promotes the search for evidence in the form of clinical trials and other studies of interventions. Visit cochrane/ for more information.
Contact: Lisa Esposito
Center for the Advancement of Health
View drug information on Arimidex; Aromasin Tablets; Femara.
четверг, 5 апреля 2012 г.
Less Alcohol Consumed By Women Involved In Leisure Activities
Women who are satisfied with everyday life and are involved in leisure activities rarely have problems with alcohol, reveals a thesis from the University of Gothenburg, Sweden.
Occupational therapist Christina Andersson, who wrote the thesis, has looked at how everyday life affects alcohol consumption as part of the wider Women and Alcohol in Gothenburg (WAG) population study which has been ongoing at the Sahlgrenska Academy since the mid-1980s.
In one study, 851 women aged 20-55 answered questions about their everyday life covering employment, leisure activities, the distribution of housework, how much time they have to themselves to do things they enjoy, and how satisfied they are in each of these areas.
"Alcohol dependence and abuse, high alcohol consumption and high episodic drinking turned out to be most common among women who, despite having more time to themselves, are less involved in leisure activities," says Andersson. "Being more involved and being satisfied with the various domains of everyday life, such as work, housework and leisure activities, has only a weak link to risk drinking, even for those with little time to themselves."
The results of another of the underlying studies showed that alcohol dependence is more common among women who drink to cope better with everyday life (for example to get to sleep or feel less down), those who drink frequently and those who drink alone. Intensive alcohol consumption is most common among those who acknowledge the social effects of drinking.
The results also point to the importance of identifying groups of individuals with different drinking patterns. Drawing attention to the needs that alcohol consumption meets in women's everyday life may be a further preventative measure.
"Identifying patterns like this can probably lead to new ideas about how preventive actions should be designed, beyond what an analysis of individual factors can achieve," says Andersson.
Source:
Christina Andersson
University of Gothenburg
Occupational therapist Christina Andersson, who wrote the thesis, has looked at how everyday life affects alcohol consumption as part of the wider Women and Alcohol in Gothenburg (WAG) population study which has been ongoing at the Sahlgrenska Academy since the mid-1980s.
In one study, 851 women aged 20-55 answered questions about their everyday life covering employment, leisure activities, the distribution of housework, how much time they have to themselves to do things they enjoy, and how satisfied they are in each of these areas.
"Alcohol dependence and abuse, high alcohol consumption and high episodic drinking turned out to be most common among women who, despite having more time to themselves, are less involved in leisure activities," says Andersson. "Being more involved and being satisfied with the various domains of everyday life, such as work, housework and leisure activities, has only a weak link to risk drinking, even for those with little time to themselves."
The results of another of the underlying studies showed that alcohol dependence is more common among women who drink to cope better with everyday life (for example to get to sleep or feel less down), those who drink frequently and those who drink alone. Intensive alcohol consumption is most common among those who acknowledge the social effects of drinking.
The results also point to the importance of identifying groups of individuals with different drinking patterns. Drawing attention to the needs that alcohol consumption meets in women's everyday life may be a further preventative measure.
"Identifying patterns like this can probably lead to new ideas about how preventive actions should be designed, beyond what an analysis of individual factors can achieve," says Andersson.
Source:
Christina Andersson
University of Gothenburg
Подписаться на:
Комментарии (Atom)